- SHL Medical has entered a non-exclusive strategic partnership with Lyophilization Technology, Inc. (LTI), a CDMO specialising in lyophilisation.
- The collaboration combines SHL’s autoinjector platform with LTI’s expertise in dual-chamber cartridges to support clinical development.
SHL Medical has formed a non-exclusive strategic partnership with Lyophilization Technology, Inc. (LTI), a contract development and manufacturing organisation (CDMO) specialising in lyophilisation of healthcare products.
The agreement, part of SHL’s alliance partnership framework, will focus on advancing lyophilised injectable drug delivery. SHL recently launched Reunite™, a dual-chamber cartridge autoinjector that automates reconstitution, supporting accurate dosing and self-administration. LTI contributes expertise in product development, process engineering and dual-chamber cartridge preparation for clinical studies in compliance with US and EU standards.
The collaboration responds to growing industry demand for patient-friendly administration of lyophilised medicines. By combining SHL’s platform with LTI’s CDMO capabilities, the companies aim to enable efficient production of clinical-grade materials and support drug developers in bringing therapies forward.
“We are excited to partner with Lyophilization Technology, Inc. to further support our customers during the critical and complex phases of feasibility assessments and clinical studies. This collaboration creates meaningful synergies that drive drug delivery innovation, streamline development timelines, and support the advancement of therapies that improve patient outcomes.”
Ralph Howald, CTO of SHL Medical
Ed Trappler, President of LTI, added that the partnership provides opportunities for developing therapies suited to home healthcare that are “safe, effective, and most comfortable to the patient.”
